Modulation of αvβ3 Integrin via Transactivation of β3 Integrin Gene on Murine Bone Marrow Macrophages by 1,25(OH)2D3, Retinoic Acid and Interleukin-4

IF 1.6 4区生物学 Q4 CELL BIOLOGY

Acta Histochemica Et Cytochemica Pub Date : 2019-08-10 DOI:10.1267/ahc.19015

S. Kitazawa, Ryuma Haraguchi, Y. Kohara, R. Kitazawa

引用次数: 1

Abstract

The interleukin (IL)-4, 1,25(OH)2D3 and retinoic acid, increase surface expression of functional integrin αvβ3 on murine osteoclast precursors. All three agonists stimulate transcription of the β3 gene, leading to increased steady-state levels of mRNA this protein. By contrast, mRNA levels of αv remain unchanged. In each instance, the increase in the surface expression of the integrin results in increased migration of the cells onto an αvβ3 substrate. Because β3 subunit, except platelet where β3 subunit conform a dimer with αIIb, associates solely with αv subunit monogamously, while promiscuous αv subunit combines with various subunit, our present data support the idea that the β3 subunit governs the surface-expressed functional integrin complex.

查看原文本刊更多论文

1,25（OH）2D3、维甲酸和白细胞介素-4反式激活小鼠骨髓巨噬细胞的β3整合素基因调节αvβ3整合素

白细胞介素(IL)- 4,1,25 (OH)2D3和维甲酸可增加小鼠破骨细胞前体表面功能性整合素αvβ3的表达。所有三种激动剂都刺激β3基因的转录，导致该蛋白mRNA的稳态水平增加。相比之下，αv的mRNA水平保持不变。在每种情况下，整合素表面表达的增加导致细胞迁移到αvβ3底物上的增加。由于除了血小板中β3亚基与αIIb为二聚体外，β3亚基仅与αv亚基单偶结合，而αv亚基与多种亚基混杂结合，我们目前的数据支持β3亚基控制表面表达的功能性整合素复合物的观点。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Acta Histochemica Et Cytochemica 生物-细胞生物学

CiteScore

3.50

自引率

8.30%

发文量

审稿时长

>12 weeks

期刊介绍： Acta Histochemica et Cytochemica is the official online journal of the Japan Society of Histochemistry and Cytochemistry. It is intended primarily for rapid publication of concise, original articles in the fields of histochemistry and cytochemistry. Manuscripts oriented towards methodological subjects that contain significant technical advances in these fields are also welcome. Manuscripts in English are accepted from investigators in any country, whether or not they are members of the Japan Society of Histochemistry and Cytochemistry. Manuscripts should be original work that has not been previously published and is not being considered for publication elsewhere, with the exception of abstracts. Manuscripts with essentially the same content as a paper that has been published or accepted, or is under consideration for publication, will not be considered. All submitted papers will be peer-reviewed by at least two referees selected by an appropriate Associate Editor. Acceptance is based on scientific significance, originality, and clarity. When required, a revised manuscript should be submitted within 3 months, otherwise it will be considered to be a new submission. The Editor-in-Chief will make all final decisions regarding acceptance.